{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:31:04Z","timestamp":1793662264159,"version":"4.5.1"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T00:00:00Z","timestamp":1749254400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T00:00:00Z","timestamp":1749254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Breast Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Inflammatory breast cancer (IBC) is a rare and aggressive form of breast cancer typically diagnosed at advanced stages. Although many cases initially respond to conventional therapies, IBC remains refractory, with high risk of recurrence due to early dissemination, tumor heterogeneity, and complex microenvironmental factors. Despite advancements in treatment, IBC poses unique challenges, particularly in community healthcare settings, where implementation of current guidelines is often limited by disease complexity and evidence gaps. Multidisciplinary care is essential and should include education on therapeutic options, lymphedema management, financial navigations, and ongoing support. To support diagnostic consistency, a consensus-driven IBC Scoring System has been developed to help clinicians identify IBC more accurately using clinical features This paper reviews best practices for managing IBC in community settings, emphasizing practical, multidisciplinary strategies that improve outcomes and presenting a framework aligns with the realities of community healthcare to ensure patients receive the highest possible standard of care.<\/jats:p>","DOI":"10.1038\/s41523-025-00765-4","type":"journal-article","created":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T12:44:10Z","timestamp":1749300250000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Inflammatory breast cancer, best practice in the community setting"],"prefix":"10.1038","volume":"11","author":[{"given":"Yoko","family":"Takahashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nithya","family":"Sridhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Iwase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Marumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jami","family":"Fukui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiesha","family":"Pradhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yee Chung","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto T.","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,7]]},"reference":[{"key":"765_CR1","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1245\/s10434-013-3439-y","volume":"21","author":"B Goldner","year":"2014","unstructured":"Goldner, B. et al. Incidence of inflammatory breast cancer in women, 1992\u20132009, United States. Ann. Surg. Oncol. 21, 1267\u20131270 (2014).","journal-title":"Ann. Surg. Oncol."},{"key":"765_CR2","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1093\/annonc\/mdy192","volume":"29","author":"F Cardoso","year":"2018","unstructured":"Cardoso, F. et al. 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4). Ann. Oncol. 29, 1634\u20131657 (2018).","journal-title":"Ann. Oncol."},{"key":"765_CR3","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s10549-015-3436-x","volume":"152","author":"TM Fouad","year":"2015","unstructured":"Fouad, T. M. et al. Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis. Breast Cancer Res. Treat. 152, 407\u2013416 (2015).","journal-title":"Breast Cancer Res. Treat."},{"key":"765_CR4","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s10549-021-06434-x","volume":"192","author":"R Jagsi","year":"2022","unstructured":"Jagsi, R. et al. Inflammatory breast cancer defined: proposed common diagnostic criteria to guide treatment and research. Breast Cancer Res. Treat. 192, 235\u2013243 (2022).","journal-title":"Breast Cancer Res. Treat."},{"key":"765_CR5","doi-asserted-by":"crossref","unstructured":"Farley, C. et al. Lymphedema in inflammatory breast cancer patients following trimodal treatment. Ann. Surg. Oncol. 29, 6370\u20136378 (2022).","DOI":"10.1245\/s10434-022-12142-7"},{"key":"765_CR6","doi-asserted-by":"publisher","first-page":"58","DOI":"10.21037\/cco-21-116","volume":"10","author":"HT Le-Petross","year":"2021","unstructured":"Le-Petross, H. T. et al. Why diagnosing inflammatory breast cancer is hard and how to overcome the challenges: a narrative review. Chin. Clin. Oncol. 10, 58 (2021).","journal-title":"Chin. Clin. Oncol."},{"key":"765_CR7","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Breast Cancer, Version 5.2024. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1419 (2024)."},{"key":"765_CR8","unstructured":"MD Anderson Cancer Center. Inflammatory Breast Cancer (IBC) Algorithm. https:\/\/www.mdanderson.org\/content\/dam\/mdanderson\/documents\/for-physicians\/algorithms\/cancer-treatment\/ca-%20treatment-breast-inflammatory-web-algorithm.pdf (2024)."},{"key":"765_CR9","unstructured":"Amin, M. B. et al. The 8th Edition of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual (AJCC, 2017)."},{"key":"765_CR10","doi-asserted-by":"publisher","first-page":"e0204372","DOI":"10.1371\/journal.pone.0204372","volume":"13","author":"TM Fouad","year":"2018","unstructured":"Fouad, T. M. et al. Distinct epidemiological profiles associated with inflammatory breast cancer (IBC): a comprehensive analysis of the IBC registry at The University of Texas MD Anderson Cancer Center. PLoS ONE 13, e0204372 (2018).","journal-title":"PLoS ONE"},{"key":"765_CR11","doi-asserted-by":"crossref","unstructured":"Lynce, F. et al. Development of a multi-institutional dataset to validate a novel inflammatory breast cancer diagnostic score. J. Natl. Cancer Inst. djaf088 (2025) [Online ahead of print].","DOI":"10.1093\/jnci\/djaf088"},{"key":"765_CR12","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1200\/JCO.2014.55.1978","volume":"32","author":"NM Rueth","year":"2014","unstructured":"Rueth, N. M. et al. Underuse of trimodality treatment affects survival for patients with inflammatory breast cancer: an analysis of treatment and survival trends from the National Cancer Database. J. Clin. Oncol. 32, 2018\u20132024 (2014).","journal-title":"J. Clin. Oncol."},{"key":"765_CR13","unstructured":"Susan, G. K. Inflammatory Breast Cancer (IBC) Scoring System. https:\/\/www.komen.org\/ibc-calculator-intro\/ (2024)."},{"key":"765_CR14","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.7150\/jca.23969","volume":"9","author":"NT Ueno","year":"2018","unstructured":"Ueno, N. T. et al. International consensus on the clinical management of inflammatory breast cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference. J. Cancer 9, 1437\u20131447 (2018).","journal-title":"J. Cancer"},{"key":"765_CR15","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.ejso.2018.05.008","volume":"44","author":"V Papalouka","year":"2018","unstructured":"Papalouka, V. & Gilbert, F. J. Inflammatory breast cancer\u2014importance of breast imaging. Eur. J. Surg. Oncol. 44, 1135\u20131138 (2018).","journal-title":"Eur. J. Surg. Oncol."},{"key":"765_CR16","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s10549-007-9671-z","volume":"109","author":"WT Yang","year":"2008","unstructured":"Yang, W. T. et al. Inflammatory breast cancer: PET\/CT, MRI, mammography, and sonography findings. Breast Cancer Res. Treat. 109, 417\u2013426 (2008).","journal-title":"Breast Cancer Res. Treat."},{"key":"765_CR17","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1148\/radiol.2233010198","volume":"223","author":"I G\u00fcnhan-Bilgen","year":"2002","unstructured":"G\u00fcnhan-Bilgen, I. et al. Inflammatory breast carcinoma: mammographic, ultrasonographic, clinical, and pathologic findings in 142 cases. Radiology 223, 829\u2013838 (2002).","journal-title":"Radiology"},{"key":"765_CR18","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s10549-017-4119-6","volume":"162","author":"RBP van Uden","year":"2017","unstructured":"van Uden, R. B. P. et al. Inflammatory breast cancer in the Netherlands; improved survival over the last decades. Breast Cancer Res. Treat. 162, 365\u2013374 (2017).","journal-title":"Breast Cancer Res. Treat."},{"key":"765_CR19","doi-asserted-by":"publisher","first-page":"W769","DOI":"10.2214\/AJR.10.6157","volume":"197","author":"HT Le-Petross","year":"2011","unstructured":"Le-Petross, H. T. et al. MRI features of inflammatory breast cancer. Am. J. Roentgenol. 197, W769\u2013W776 (2011).","journal-title":"Am. J. Roentgenol."},{"key":"765_CR20","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/RUQ.0000000000000535","volume":"37","author":"VT Le","year":"2020","unstructured":"Le, V. T. et al. A comparison of the diagnostic value of positron emission tomography\/computed tomography and ultrasound for the detection of metastatic axillary nodal disease in treatment\u2011naive breast cancer. Ultrasound Q. 37, 28\u201333 (2020).","journal-title":"Ultrasound Q."},{"key":"765_CR21","doi-asserted-by":"publisher","first-page":"8610","DOI":"10.1245\/s10434-021-10148-1","volume":"28","author":"LM Postlewait","year":"2021","unstructured":"Postlewait, L. M. et al. Contralateral axillary metastasis in patients with inflammatory breast cancer. Ann. Surg. Oncol. 28, 8610\u20138621 (2021).","journal-title":"Ann. Surg. Oncol."},{"key":"765_CR22","doi-asserted-by":"publisher","first-page":"7326","DOI":"10.1245\/s10434-024-15713-y","volume":"31","author":"AC Glencer","year":"2024","unstructured":"Glencer, A. C. et al. Self\u2011reported management of inflammatory breast cancer among the American Society of Breast Surgeons membership: consensus and opportunities. Ann. Surg. Oncol. 31, 7326\u20137334 (2024).","journal-title":"Ann. Surg. Oncol."},{"key":"765_CR23","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s12282-012-0346-1","volume":"19","author":"T Uematsu","year":"2012","unstructured":"Uematsu, T. et al. MRI findings of inflammatory breast cancer, locally advanced breast cancer, and acute mastitis: T2-weighted images can increase the specificity of inflammatory breast cancer. Breast Cancer 19, 289\u2013294 (2012).","journal-title":"Breast Cancer"},{"key":"765_CR24","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1148\/radiol.2015150796","volume":"279","author":"C Iacconi","year":"2016","unstructured":"Iacconi, C. et al. Multicentric cancer detected at breast MR imaging and not at mammography: important or not?. Radiology 279, 378\u2013384 (2016).","journal-title":"Radiology"},{"key":"765_CR25","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s10549-020-05631-4","volume":"181","author":"H Jacene","year":"2020","unstructured":"Jacene, H. et al. Discrepancy between FDG-PET\/CT and contrast-enhanced CT in the staging of patients with inflammatory breast cancer: implications for treatment planning. Breast Cancer Res. Treat. 181, 383\u2013390 (2020).","journal-title":"Breast Cancer Res. Treat."},{"key":"765_CR26","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1016\/j.ijrobp.2011.10.040","volume":"83","author":"GV Walker","year":"2012","unstructured":"Walker, G. V. et al. Pretreatment staging positron emission tomography\/computed tomography in patients with inflammatory breast cancer influences radiation treatment field designs. Int. J. Radiat. Oncol. Biol. Phys. 83, 1381\u20131386 (2012).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"765_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.102943","volume":"151","author":"DJP van Uden","year":"2020","unstructured":"van Uden, D. J. P. et al. 18F] FDG PET\/CT in the staging of inflammatory breast cancer: a systematic review. Crit. Rev. Oncol. Hematol. 151, 102943 (2020).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"765_CR28","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.amjsurg.2022.11.017","volume":"225","author":"SA Valente","year":"2023","unstructured":"Valente, S. A. et al. Inflammatory breast cancer and the importance of skin punch biopsy. Am. J. Surg. 225, 549\u2013552 (2023).","journal-title":"Am. J. Surg."},{"key":"765_CR29","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/annonc\/mdq345","volume":"22","author":"S Dawood","year":"2011","unstructured":"Dawood, S. et al. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann. Oncol. 22, 515\u2013523 (2011).","journal-title":"Ann. Oncol."},{"key":"765_CR30","doi-asserted-by":"publisher","first-page":"642","DOI":"10.5858\/arpa.2014-0200-OA","volume":"139","author":"JS Ross","year":"2015","unstructured":"Ross, J. S. et al. Genomic profiling of advanced-stage, metaplastic breast carcinoma by next-generation sequencing reveals frequent, targetable genomic abnormalities and potential new treatment options. Arch. Pathol. Lab Med. 139, 642\u2013649 (2015).","journal-title":"Arch. Pathol. Lab Med."},{"key":"765_CR31","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s10549-017-4165-0","volume":"163","author":"N Matsuda","year":"2017","unstructured":"Matsuda, N. et al. Identification of frequent somatic mutations in inflammatory breast cancer. Breast Cancer Res. Treat. 163, 263\u2013272 (2017).","journal-title":"Breast Cancer Res. Treat."},{"key":"765_CR32","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1158\/1535-7163.MCT-15-0353","volume":"15","author":"CA Hamm","year":"2016","unstructured":"Hamm, C. A. et al. Genomic and immunological tumor profiling identifies targetable pathways and extensive CD8+\/PDL1+ immune infiltration in inflammatory breast cancer tumors. Mol. Cancer Ther. 15, 1746\u20131756 (2016).","journal-title":"Mol. Cancer Ther."},{"key":"765_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-018-1007-x","volume":"20","author":"L Xu","year":"2018","unstructured":"Xu, L. et al. Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer. Breast Cancer Res. 20, 88 (2018).","journal-title":"Breast Cancer Res."},{"key":"765_CR34","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1002\/1878-0261.12621","volume":"14","author":"F Bertucci","year":"2020","unstructured":"Bertucci, F. et al. NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancers. Mol. Oncol. 14, 504\u2013519 (2020).","journal-title":"Mol. Oncol."},{"key":"765_CR35","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.breast.2023.01.010","volume":"69","author":"C Richard","year":"2023","unstructured":"Richard, C. et al. Comparison of the genomic alterations present in tumor samples from patients with metastatic inflammatory versus non-inflammatory breast cancer reveals AURKA as a potential treatment target. Breast 69, 476\u2013480 (2023).","journal-title":"Breast"},{"key":"765_CR36","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.3390\/cancers12102816","volume":"12","author":"N Fadoni","year":"2020","unstructured":"Fadoni, N. et al. Inflammatory breast cancer: clinical implications of genomic alterations and mutational profiling. Cancers 12, 2816 (2020).","journal-title":"Cancers"},{"key":"765_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-021-00879-x","volume":"13","author":"Y Li","year":"2021","unstructured":"Li, Y. et al. Whole-genome sequencing of phenotypically distinct inflammatory breast cancers reveals similar genomic alterations to non-inflammatory breast cancers. Genome Med. 13, 70 (2021).","journal-title":"Genome Med."},{"key":"765_CR38","doi-asserted-by":"publisher","unstructured":"Priedigkeit, N. et al. Clinicogenomic characterization of inflammatory breast cancer. Clin. Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-2081 (2025). Online ahead of print.","DOI":"10.1158\/1078-0432.CCR-24-2081"},{"key":"765_CR39","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41698-024-00729-0","volume":"8","author":"X Wang","year":"2024","unstructured":"Wang, X. et al. Genomic and transcriptomic analyses identify distinctive features of triple\u2011negative inflammatory breast cancer. NPJ Precis. Oncol. 8, 265 (2024).","journal-title":"NPJ Precis. Oncol."},{"key":"765_CR40","doi-asserted-by":"publisher","first-page":"4265","DOI":"10.1245\/s10434-020-09392-8","volume":"28","author":"N Partain","year":"2021","unstructured":"Partain, N. et al. The role of mastectomy in de novo stage IV inflammatory breast cancer. Ann. Surg. Oncol. 28, 4265\u20134274 (2021).","journal-title":"Ann. Surg. Oncol."},{"key":"765_CR41","first-page":"SP434","volume":"28","author":"M Gavidia","year":"2022","unstructured":"Gavidia, M. et al. Multidisciplinary care as the catalyst for innovation in oncology. Evid. Based Oncol. 28, SP434\u2013SP437 (2022).","journal-title":"Evid. Based Oncol."},{"key":"765_CR42","doi-asserted-by":"publisher","first-page":"e354","DOI":"10.1016\/j.clbc.2023.05.013","volume":"23","author":"MM Hussain","year":"2023","unstructured":"Hussain, M. M. et al. Implementation of a multidisciplinary inflammatory breast cancer program for quality improvement. Clin. Breast Cancer 23, e354\u2013e358 (2023).","journal-title":"Clin. Breast Cancer"},{"key":"765_CR43","doi-asserted-by":"publisher","first-page":"142","DOI":"10.5114\/pdia.2015.48069","volume":"33","author":"A Reich","year":"2016","unstructured":"Reich, A. et al. Carcinoma en cuirasse as an initial manifestation of inflammatory breast cancer. Postepy Dermatol. Alergol. 33, 142\u2013145 (2016).","journal-title":"Postepy Dermatol. Alergol."},{"key":"765_CR44","unstructured":"Mordenti, C. et al. Cutaneous metastatic breast carcinoma: a study of 164 patients. Acta Dermatovenerologica Alpina Pannonica et Adriatica. 9, 143\u2013148 (2000)."},{"key":"765_CR45","doi-asserted-by":"publisher","first-page":"5461","DOI":"10.1245\/s10434-021-10522-z","volume":"28","author":"T Adesoye","year":"2021","unstructured":"Adesoye, T. et al. Current surgical management of inflammatory breast cancer. Ann. Surg. Oncol. 28, 5461\u20135467 (2021).","journal-title":"Ann. Surg. Oncol."},{"key":"765_CR46","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1007\/s11864-023-01077-0","volume":"24","author":"AB Newman","year":"2023","unstructured":"Newman, A. B. et al. Tailoring treatment for patients with inflammatory breast cancer. Curr. Treat. Options Oncol. 24, 580\u2013593 (2023).","journal-title":"Curr. Treat. Options Oncol."},{"key":"765_CR47","doi-asserted-by":"publisher","first-page":"6232","DOI":"10.1245\/s10434-023-13906-5","volume":"30","author":"T Adesoye","year":"2023","unstructured":"Adesoye, T. et al. Low rates of local-regional recurrence among inflammatory breast cancer patients after contemporary trimodal therapy. Ann. Surg. Oncol. 30, 6232\u20136240 (2023).","journal-title":"Ann. Surg. Oncol."},{"key":"765_CR48","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.surg.2021.08.061","volume":"171","author":"T Relation","year":"2022","unstructured":"Relation, T. et al. Inflammatory breast cancer, trimodal treatment, and mortality: does where you live matter?. Surgery 171, 687\u2013692 (2022).","journal-title":"Surgery"},{"key":"765_CR49","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1093\/annonc\/mdn728","volume":"20","author":"PJ Barrett-Lee","year":"2009","unstructured":"Barrett-Lee, P. J. et al. Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk. Ann. Oncol. 20, 816\u2013827 (2009).","journal-title":"Ann. Oncol."},{"key":"765_CR50","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1158\/1538-7445.SABCS15-S5-04","volume":"76","author":"DJ Slamon","year":"2016","unstructured":"Slamon, D. J. et al. Abstract S5-04: Ten year follow-up of BCIRG-006 comparing doxorubicin plus cyclophosphamide followed by docetaxel (AC\u2192T) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (AC\u2192TH) with docetaxel, carboplatin and trastuzumab (TCH). Cancer Res. 76, S5\u2013S04 (2016).","journal-title":"Cancer Res."},{"key":"765_CR51","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ejca.2017.10.021","volume":"89","author":"A Schneeweiss","year":"2018","unstructured":"Schneeweiss, A. et al. Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. Eur. J. Cancer 89, 27\u201335 (2018).","journal-title":"Eur. J. Cancer"},{"key":"765_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100461","volume":"7","author":"V Guarneri","year":"2022","unstructured":"Guarneri, V. et al. Anthracyclines in the treatment of patients with early breast cancer. ESMO Open 7, 100461 (2022).","journal-title":"ESMO Open"},{"key":"765_CR53","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.1200\/JCO.2016.71.4147","volume":"35","author":"JL Blum","year":"2017","unstructured":"Blum, J. L. et al. Anthracyclines in early breast cancer: the ABC Trials\u2014USOR 06-090, NSABP B-46-I\/USOR 07132, and NSABP B-49 (NRG Oncology). J. Clin. Oncol. 35, 2647\u20132655 (2017).","journal-title":"J. Clin. Oncol."},{"key":"765_CR54","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1001\/jamaoncol.2023.5033","volume":"10","author":"P Sharma","year":"2024","unstructured":"Sharma, P. et al. Clinical and biomarker findings of neoadjuvant pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer: NeoPACT phase 2 clinical trial. JAMA Oncol. 10, 227\u2013235 (2024).","journal-title":"JAMA Oncol."},{"key":"765_CR55","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar, P. et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384, 164\u2013172 (2014).","journal-title":"Lancet"},{"key":"765_CR56","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s10549-016-4017-3","volume":"160","author":"A Brzezinska","year":"2016","unstructured":"Brzezinska, A. et al. Outcomes of patients with inflammatory breast cancer treated by breast-conserving surgery. Breast Cancer Res. Treat. 160, 387\u2013391 (2016).","journal-title":"Breast Cancer Res. Treat."},{"key":"765_CR57","doi-asserted-by":"publisher","first-page":"5383","DOI":"10.1245\/s10434-022-12037-7","volume":"29","author":"TJ Hieken","year":"2022","unstructured":"Hieken, T. J. et al. Inflammatory breast cancer: durable breast cancer-specific survival for HER2-positive patients with a pathologic complete response to neoadjuvant therapy. Ann. Surg. Oncol. 29, 5383\u20135386 (2022).","journal-title":"Ann. Surg. Oncol."},{"key":"765_CR58","doi-asserted-by":"publisher","first-page":"1372633","DOI":"10.3389\/fonc.2024.1372633","volume":"14","author":"L Scardina","year":"2024","unstructured":"Scardina, L. et al. Conserving surgery in inflammatory breast cancer after neoadjuvant chemotherapy in patients with clinical complete response: the ConSIBreC randomized controlled trial. Front. Oncol. 14, 1372633 (2024).","journal-title":"Front. Oncol."},{"key":"765_CR59","doi-asserted-by":"publisher","first-page":"262e","DOI":"10.1097\/PRS.0000000000000900","volume":"135","author":"EI Chang","year":"2015","unstructured":"Chang, E. I. et al. Challenging a traditional paradigm: 12-year experience with autologous free flap breast reconstruction for inflammatory breast cancer. Plast. Reconstr. Surg. 135, 262e\u2013269e (2015).","journal-title":"Plast. Reconstr. Surg."},{"key":"765_CR60","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1245\/s10434-016-5554-z","volume":"23","author":"AB Simpson","year":"2016","unstructured":"Simpson, A. B. et al. Immediate reconstruction in inflammatory breast cancer: challenging current care. Ann. Surg. Oncol. 23, 642\u2013648 (2016).","journal-title":"Ann. Surg. Oncol."},{"key":"765_CR61","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/S0360-3016(00)00561-7","volume":"47","author":"Z Liao","year":"2000","unstructured":"Liao, Z. et al. Locoregional irradiation for inflammatory breast cancer: effectiveness of dose escalation in decreasing recurrence. Int. J. Radiat. Oncol. Biol. Phys. 47, 1191\u20131200 (2000).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"765_CR62","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.ijrobp.2014.01.054","volume":"89","author":"L Brown","year":"2014","unstructured":"Brown, L. et al. Once-daily radiation therapy for inflammatory breast cancer. Int. J. Radiat. Oncol. Biol. Phys. 89, 997\u20131003 (2014).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"765_CR63","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1200\/JCO.21.02006","volume":"40","author":"SA Khan","year":"2022","unstructured":"Khan, S. A. et al. Early local therapy for the primary site in de novo stage IV breast cancer: results of a randomized clinical trial (E2108). J. Clin. Oncol. 40, 978\u2013987 (2022).","journal-title":"J. Clin. Oncol."},{"key":"765_CR64","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.suronc.2020.01.005","volume":"33","author":"DJP van Uden","year":"2020","unstructured":"van Uden, D. J. P. et al. Better survival after surgery of the primary tumor in stage IV inflammatory breast cancer. Surg. Oncol. 33, 43\u201350 (2020).","journal-title":"Surg. Oncol."},{"key":"765_CR65","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine; 2000\u2013. Available from: https:\/\/clinicaltrials.gov\/ (accessed 11 April 2025)."},{"key":"765_CR66","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1470-2045(12)70049-9","volume":"13","author":"J-Y Pierga","year":"2012","unstructured":"Pierga, J.-Y. et al. Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study. Lancet Oncol. 13, 375\u2013384 (2012).","journal-title":"Lancet Oncol."},{"key":"765_CR67","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa1105195","volume":"365","author":"RE Coleman","year":"2011","unstructured":"Coleman, R. E. et al. Breast cancer adjuvant therapy with zoledronic acid. N. Engl. J. Med. 365, 1396\u20131405 (2011).","journal-title":"N. Engl. J. Med."},{"key":"765_CR68","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1093\/annonc\/mdr344","volume":"23","author":"KD Miller","year":"2012","unstructured":"Miller, K. D. et al. A phase II pilot trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node positive breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group. Ann. Oncol. 23, 331\u2013337 (2012).","journal-title":"Ann. Oncol."},{"key":"765_CR69","doi-asserted-by":"publisher","first-page":"2758","DOI":"10.1002\/cncr.25171","volume":"116","author":"H Yamauchi","year":"2010","unstructured":"Yamauchi, H. et al. Targeted therapy in inflammatory breast cancer. Cancer 116, 2758\u20132759 (2010).","journal-title":"Cancer"},{"key":"765_CR70","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1001\/jamaoncol.2018.1436","volume":"4","author":"N Matsuda","year":"2018","unstructured":"Matsuda, N. et al. Safety and efficacy of panitumumab plus neoadjuvant chemotherapy in patients with primary HER2-negative inflammatory breast cancer. JAMA Oncol. 4, 1207\u20131213 (2018).","journal-title":"JAMA Oncol."},{"key":"765_CR71","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa1111065","volume":"366","author":"G von Minckwitz","year":"2012","unstructured":"von Minckwitz, G. et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N. Engl. J. Med. 366, 299\u2013309 (2012).","journal-title":"N. Engl. J. Med."},{"key":"765_CR72","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/S1470-2045(16)00011-5","volume":"17","author":"F Bertucci","year":"2016","unstructured":"Bertucci, F. et al. Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study. Lancet Oncol. 17, 600\u2013611 (2016).","journal-title":"Lancet Oncol."},{"key":"765_CR73","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","volume":"13","author":"L Gianni","year":"2012","unstructured":"Gianni, L. et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 13, 25\u201332 (2012).","journal-title":"Lancet Oncol."},{"key":"765_CR74","doi-asserted-by":"publisher","first-page":"PO3-20-06","DOI":"10.1158\/1538-7445.SABCS23-PO3-20-06","volume":"84","author":"P Tarantino","year":"2024","unstructured":"Tarantino, P. et al. Abstract PO3-20-06: TRUDI: a phase II study of neoadjuvant TRastuzumab derUxtecan and Durvalumab for stage III HER2-expressing inflammatory breast cancer. Cancer Res. 84, PO3-20-06 (2024).","journal-title":"Cancer Res."},{"key":"765_CR75","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-023-00508-3","volume":"9","author":"V Debien","year":"2023","unstructured":"Debien, V. et al. Immunotherapy in breast cancer: an overview of current strategies and perspectives. NPJ Breast Cancer 9, 7 (2023).","journal-title":"NPJ Breast Cancer"},{"key":"765_CR76","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1200\/JOP.18.00141","volume":"15","author":"P Tandra","year":"2019","unstructured":"Tandra, P. et al. Identification and management of lymphedema in patients with breast cancer. J. Oncol. Pr. 15, 255\u2013262 (2019).","journal-title":"J. Oncol. Pr."},{"key":"765_CR77","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/S1470-2045(13)70076-7","volume":"14","author":"T DiSipio","year":"2013","unstructured":"DiSipio, T. et al. Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. Lancet Oncol. 14, 500\u2013515 (2013).","journal-title":"Lancet Oncol."},{"key":"765_CR78","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1055\/a-2182-1015","volume":"40","author":"R Copeland-Halperin","year":"2024","unstructured":"Copeland-Halperin, R. et al. Preoperative risk factors for lymphedema in inflammatory breast cancer. J. Reconstr. Microsurg. 40, 311\u2013317 (2024).","journal-title":"J. Reconstr. Microsurg."},{"key":"765_CR79","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-014-0414-x","volume":"16","author":"K Togawa","year":"2014","unstructured":"Togawa, K. et al. Risk factors for self-reported arm lymphedema among female breast cancer survivors: a prospective cohort study. Breast Cancer Res. 16, 414 (2014).","journal-title":"Breast Cancer Res."},{"key":"765_CR80","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1001\/jamaoncol.2022.1628","volume":"8","author":"G Montagna","year":"2022","unstructured":"Montagna, G. et al. Risk factors and racial and ethnic disparities in patients with breast cancer-related lymphedema. JAMA Oncol. 8, 1195\u20131200 (2022).","journal-title":"JAMA Oncol."},{"key":"765_CR81","doi-asserted-by":"publisher","first-page":"S234","DOI":"10.1097\/SAP.0000000000001864","volume":"82","author":"AR Johnson","year":"2019","unstructured":"Johnson, A. R. et al. Lymphedema incidence after axillary lymph node dissection: quantifying the impact of radiation and the lymphatic microsurgical preventive healing approach. Ann. Plast. Surg. 82, S234\u2013S241 (2019).","journal-title":"Ann. Plast. Surg."},{"key":"765_CR82","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/PRS.0000000000009857","volume":"151","author":"AS Levy","year":"2023","unstructured":"Levy, A. S. et al. Lymphatic microsurgical preventive healing approach for the primary prevention of lymphedema: a 4-year follow-up. Plast. Reconstr. Surg. 151, 413\u2013420 (2023).","journal-title":"Plast. Reconstr. Surg."},{"key":"765_CR83","doi-asserted-by":"crossref","unstructured":"Sanders, J. J. et al. Palliative care for patients with cancer: ASCO guideline update. J. Clin. Oncol. 42, 2336\u20132357 (2024).","DOI":"10.1200\/JCO.24.00542"},{"key":"765_CR84","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1245\/s10434-015-4469-4","volume":"22","author":"LEG Warren","year":"2015","unstructured":"Warren, L. E. G. et al. Inflammatory breast cancer: patterns of failure and the case for aggressive locoregional management. Ann. Surg. Oncol. 22, 2483\u20132491 (2015).","journal-title":"Ann. Surg. Oncol."},{"key":"765_CR85","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717X-9-126","volume":"9","author":"K Steinauer","year":"2014","unstructured":"Steinauer, K. et al. Radiotherapy in patients with distant metastatic breast cancer. Radiat. Oncol. 9, 126 (2014).","journal-title":"Radiat. Oncol."},{"key":"765_CR86","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/7574946","volume":"2017","author":"RA Denu","year":"2017","unstructured":"Denu, R. A. et al. Racial and socioeconomic disparities are more pronounced in inflammatory breast cancer than other breast cancers. J. Cancer Epidemiol. 2017, 7574946 (2017).","journal-title":"J. Cancer Epidemiol."},{"key":"765_CR87","doi-asserted-by":"publisher","first-page":"3344","DOI":"10.7150\/jca.31176","volume":"10","author":"GR Devi","year":"2019","unstructured":"Devi, G. R. et al. Perspectives on inflammatory breast cancer (IBC) research, clinical management and community engagement from the Duke IBC Consortium. J. Cancer 10, 3344\u20133351 (2019).","journal-title":"J. Cancer"},{"key":"765_CR88","doi-asserted-by":"crossref","unstructured":"Schinkel, J. K. et al. Racial\/ethnic differences in breast cancer survival by inflammatory histology and hormonal receptor status: an analysis of the Surveillance, Epidemiology, and End Results data. Cancer Causes Control 25, 959\u2013968 (2014).","DOI":"10.1007\/s10552-014-0395-1"},{"key":"765_CR89","doi-asserted-by":"publisher","first-page":"e2718","DOI":"10.1136\/bmj.e2718","volume":"344","author":"EM Kesson","year":"2012","unstructured":"Kesson, E. M. et al. Effects of multidisciplinary team working on breast cancer survival: retrospective, comparative, interventional cohort study of 13,722 women. BMJ 344, e2718 (2012).","journal-title":"BMJ"},{"key":"765_CR90","doi-asserted-by":"publisher","first-page":"e2454513","DOI":"10.1001\/jamanetworkopen.2024.54513","volume":"8","author":"WA Woodward","year":"2025","unstructured":"Woodward, W. A. Deescalation perils in inflammatory breast cancer. JAMA Netw. Open 8, e2454513 (2025).","journal-title":"JAMA Netw. Open"},{"key":"765_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101026","volume":"14","author":"P Chakraborty","year":"2021","unstructured":"Chakraborty, P. et al. Gene expression profiles of inflammatory breast cancer reveal high heterogeneity across the epithelial-hybrid-mesenchymal spectrum. Transl. Oncol. 14, 101026 (2021).","journal-title":"Transl. Oncol."},{"key":"765_CR92","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s10549-017-4176-x","volume":"163","author":"C Bingham","year":"2017","unstructured":"Bingham, C. et al. Mutational studies on single circulating tumor cells isolated from the blood of inflammatory breast cancer patients. Breast Cancer Res. Treat. 163, 219\u2013230 (2017).","journal-title":"Breast Cancer Res. Treat."},{"key":"765_CR93","doi-asserted-by":"publisher","unstructured":"Austin, L. et al. Abstract P2-04-03: Circulating tumor DNA (ctDNA) provides molecular monitoring for inflammatory breast cancer (IBC). AACR Annual Meeting. https:\/\/doi.org\/10.1158\/1538-7445.SABCS14-P2-04-03 (2015).","DOI":"10.1158\/1538-7445.SABCS14-P2-04-03"},{"key":"765_CR94","doi-asserted-by":"publisher","unstructured":"Alexander, A. et al. Abstract e12523: ctDNA detection before and during systemic therapy for inflammatory breast cancer. ASCO Annual Meeting. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.e12523 (2023).","DOI":"10.1200\/JCO.2023.41.16_suppl.e12523"}],"container-title":["npj Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41523-025-00765-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-025-00765-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-025-00765-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T18:02:47Z","timestamp":1749319367000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41523-025-00765-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,7]]},"references-count":94,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["765"],"URL":"https:\/\/doi.org\/10.1038\/s41523-025-00765-4","relation":{},"ISSN":["2374-4677"],"issn-type":[{"value":"2374-4677","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,7]]},"assertion":[{"value":"22 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"52"}}